In situ gastric floating gel of atazanavir sulphate for sustained release: formulation, optimization and evaluation.
| Autor: | Masareddy R; Department of Pharmaceutics, KLE College of Pharmacy, Belagavi, KLE Academy of Higher Education & Research, Belagavi, Karnataka, 590010, India., Sandure P; Department of Pharmaceutics, KLE College of Pharmacy, Belagavi, KLE Academy of Higher Education & Research, Belagavi, Karnataka, 590010, India., Patil A; Department of Pharmaceutics, KLE College of Pharmacy, Belagavi, KLE Academy of Higher Education & Research, Belagavi, Karnataka, 590010, India., Gaude Y; Department of Pharmaceutics, KLE College of Pharmacy, Belagavi, KLE Academy of Higher Education & Research, Belagavi, Karnataka, 590010, India., Patil A; Department of Pharmaceutics, KLE College of Pharmacy, Belagavi, KLE Academy of Higher Education & Research, Belagavi, Karnataka, 590010, India. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Therapeutic delivery [Ther Deliv] 2023 Oct; Vol. 14 (10), pp. 619-633. Date of Electronic Publication: 2023 Dec 06. |
| DOI: | 10.4155/tde-2023-0037 |
| Abstrakt: | Aim: Atazanavir sulphate belongs to BCS class II drug, its oral bioavailability is limited due to its rapid first-pass metabolism and P-gp efflux. Materials & methods: The in situ floating gel using the complexed drug was prepared by ion gelation method and optimized the formulation as per 3 2 full factorial design. Results: Floating lag time of optimized formulation was found to be 18 s and percentage drug release of 94.18 ± 0.18 % at the end of 16 h. The concentration of gelling polymer affects drug release and a floating lag time and vice versa . Conclusion: In situ floating gel of atazanavir sulphate was found promising to sustain drug release due to an increased gastric residence time, which leads to enhanced potential therapy. |
| Databáze: | MEDLINE |
| Externí odkaz: |
|